Related Experiment Video
Updated: Jun 27, 2026
09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Understanding and Overcoming Osteosarcoma Heterogeneity.
Sukjoo Cho1,2, Katherine Shelmidine2,3, Jason T Yustein1,2
1Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA 30329, USA.
Biomolecules
|June 26, 2026
Summary
Osteosarcoma (OS) is a complex bone cancer. Understanding its tumor heterogeneity is key to developing new therapies beyond current standards, aiming for improved patient outcomes.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- Osteosarcoma (OS) is the most common primary bone cancer in young adults.
- Current standard treatments (surgery and chemotherapy) have not advanced in over 40 years.
- Tumor heterogeneity presents a significant challenge to developing effective OS therapies.
Purpose of the Study:
- To review current evidence on OS heterogeneity.
- To discuss strategies for overcoming therapeutic barriers posed by OS heterogeneity.
Main Methods:
- Comprehensive literature review of preclinical and clinical studies on OS heterogeneity.
- Analysis of genomic, microenvironmental, epigenetic, and metabolic factors contributing to OS diversity.
- Evaluation of emerging therapeutic strategies targeting OS heterogeneity.
Main Results:
- OS heterogeneity is driven by complex somatic genomics (instability, gene alterations), germline vulnerabilities, and a diverse tumor microenvironment.
- Lineage plasticity, epigenetic, and metabolomic mechanisms also contribute to OS complexity.
- Current research explores novel biomarkers, preclinical models, and combination therapies (TKIs, immunotherapy, epigenetic/metabolic modifiers).
Conclusions:
- Addressing OS heterogeneity requires multifaceted therapeutic strategies beyond surgery and chemotherapy.
- Identifying actionable biomarkers and developing novel combination therapies are crucial for advancing OS treatment.
- Further research into the drivers of OS heterogeneity is essential for accelerating therapeutic progress.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...